PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable. Algeria’s youthful pharmaceutical landscape includes an array of state-controlled entities of an industrial or commercial nature alongside more conventional regulatory apparatus.
THE NATIONAL AGENCY FOR HEALTHCARE EQUIPMENT AND MANAGEMENT OF HEALTH INFRASTRUCTURES (AREES)
Delegate project manager to manage, on behalf of the state, transactions or services contributing to the realization of health sector investment projects, and secondly, to supervise provision of health equipment based on a list established by the Ministry of Health.
L’INSTITUT PASTEUR D’ALGÉRIE (IPA)
The IPA enjoys exclusive import and distribution rights for serums and vaccines. It plays a critical role in epidemiological surveillance: acting as the national reference point for the identification of infectious and parasitic disease and tasked with the development of tools and training schemes to counter these disease categories.
The national pharmaceutical company is run as private enterprise enjoying full managerial autonomy despite being 80% state-owned. Its dual mission comprises: consolidating its lead position as local generic manufacturer and furthering the cause of national drug policy implemented by the government as controlling shareholder.
LABORATOIRE NATIONAL DE CONTRÔLE DES PRODUITS PHARMACEUTIQUES (LNCPP)
Algeria’s national pharmaceutical regulator undertakes quality control and evaluation duties alongside research and training functions. It also enjoys World Health Organisation (WHO) status as an Africa and the Middle East – wide reference laboratory.
PHARMACIE CENTRALE DES HÔPITAUX (PCH)
The PCH is responsible for the acquisition, stockage management, regulation and supply of pharmaceuticals to the country’s public health institutions. It is also charged with maintaining strategic and contingency stocks and itself engages in local production.